Trial 4P-13-8


A randomized open-label phase IIa study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide in subjects with castration-resistant prostate cancer who have bone metastases

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic, Radiation: External
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  David Quinn, M.D.
Other Trial Staff:  Lagrimas Ilagan, D.M., Roberto Tejada, D.M., Taison Tran, Coordinator, Yvette Viverette, R.N., Elysse Faye Ballon, Coordinator, Torsten Fischer, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.